Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CMS To Meet With NASPE/HRS, Manufacturers To Review ICD Decision Process

This article was originally published in The Gray Sheet

Executive Summary

Guidant maintains that its MADIT-II trial ethically could not have been extended to provide more evidence of the long-term benefits of ICDs for the entire study population
Advertisement

Related Content

SCD-HeFT Results Justify Expanded ICD Coverage – Medtronic’s Stanton
Expanded ICD Patient Pool Augured By New Sub-Studies, Design Features
CMS National Non-Coverage Reversed For Electromagnetic Wound Therapy
Scully’s Successor Awaited By Device Reps: Will Improved Access Continue?
Cost-Effectiveness Analyses To Determine Payment On Horizon – Waldmann
Visudyne/PDT Treatment “More Effective” Than Placebo – MCAC
St. Jude Claims 3-Point ICD Market Share Gain Since CRT Competition Began
MTWA Testing Would Lead To More ICD Referrals – Medtronic
Defibrillator Coverage Decision Restricted By QRS Data That MCAC Missed
Defibrillator Coverage Decision Restricted By QRS Data That MCAC Missed
Advertisement
UsernamePublicRestriction

Register

MT018536

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel